{"filing":{"accession_number":"0001708599-26-000054","cik":"0001708599","ticker":"SER","company_name":"Serina Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ser-20260909.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/ser-20260909.htm"},"events":[{"id":32197,"run_id":29578,"accession_number":"0001708599-26-000054","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Serina announced that its Independent Safety Monitoring Committee has recommended advancement of SER-252 from Cohort 1 to Cohort 2 in a Phase 1b registrational study for advanced Parkinson's disease, with positive preliminary pharmacokinetic and exploratory clinical observations. This is a material clinical development milestone for a clinical-stage biotech company's lead program, but does not fit the specific event types (earnings, M\u0026A, litigation, etc.); it is a significant operational/strategic advancement in the drug development pipeline that would affect investor assessment of the company's progress.","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35310,"accession_number":"0001708599-26-000054","item_number":"8.01","item_title":"Other Items.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Serina announced that its Independent Safety Monitoring Committee has recommended advancement of SER-252 from Cohort 1 to Cohort 2 in a Phase 1b registrational study for advanced Parkinson's disease, with positive preliminary pharmacokinetic and exploratory clinical observations. This is a material clinical development milestone for a clinical-stage biotech company's lead program, but does not fit the specific event types (earnings, M\u0026A, litigation, etc.); it is a significant operational/strategic advancement in the drug development pipeline that would affect investor assessment of the company's progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:44:39.676493+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35310,"accession_number":"0001708599-26-000054","item_number":"8.01","item_title":"Other Items.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Serina announced that its Independent Safety Monitoring Committee has recommended advancement of SER-252 from Cohort 1 to Cohort 2 in a Phase 1b registrational study for advanced Parkinson's disease, with positive preliminary pharmacokinetic and exploratory clinical observations. This is a material clinical development milestone for a clinical-stage biotech company's lead program, but does not fit the specific event types (earnings, M\u0026A, litigation, etc.); it is a significant operational/strategic advancement in the drug development pipeline that would affect investor assessment of the company's progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:44:39.676493+00:00","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-09-09"}]}